Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ences.  Key hormones, including adiponectin and leptin, also showed changes characteristic of non-PWS obese patients, demonstrating that the drug was highly active in these patients and had a similar effect to that seen in non-PWS patients.

"These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design," explained Dr. Jennifer Miller, Associate Professor of Pediatric Endocrinology, University of Florida, and Principal Investigator for the study.  "PWS is a complex genetic disease that is difficult to treat and the results of this trial demonstrate that beloranib has a beneficial impact on this underserved patient population.  Notably, we were encouraged by reports of fullness, a first-time occurrence for PWS patients who otherwise lack the capacity to feel sated after meals."

"PWS patients remain severely impacted by their disease and are not treatable with other anti-obesity agents," added Janalee Heinemann, Director of Research & Medical Affairs for the Prader-Willi Syndrome Association (USA).  "PWS represents one of the most severe forms of genetic obesity and we welcome these results, which are a significant step towards finding a treatment for those suffering from this life threatening condition."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients with and without PWS.  This study was a randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of a dose range of beloranib administered as twice-weekly subcutaneous injections for four weeks.  The randomized treatment part of the study was follow
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... , Nov. 23, 2014  Aurobindo Pharma ... of Gabapentin Capsules, USP 300 mg 100-count bottles to ... to contain some empty capsules. Empty capsules ... adverse health consequences that could range from no effect, ... or status epilepticus (long period seizures) that could be ...
(Date:11/22/2014)... BEACH, Calif. , Nov. 21, 2014   Long ... Dental implants are often called the gold standard in tooth ... They are a stable, long-lasting way to restore and preserve ... dental implants to replace a missing tooth or as a ... completely transform the look and feel of a smile. ...
(Date:11/22/2014)... , Nov. 21, 2014 Many ... Undoubtedly, the growing influence of patients in the ... marketing interactions. Now, more than ever, understanding how ... for medical products is essential. ... Practices, LLC, benchmarked companies spent about two-thirds of ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... that the New York Stock Exchange (the "NYSE") has notified ... rules due to the Company,s failure to timely file its ... Commission. Under NYSE rules, when a Company ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... of modafinil tablets, a generic version of Teva,s Provigil® ... the Provigil® product.  Par acquired the U.S. marketing rights ... of Cephalon in 2011.  According to IMS Health data, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2Par Pharmaceutical Begins Shipment of Generic Provigil® 2
(Date:11/24/2014)... TX (PRWEB) November 24, 2014 The ... all of the wrong ingredients. Consistently consuming a diet ... to develop stores of excess fat that typically accumulate ... problems and rearing its ugly head in the form ... , When dieters make the decision to rid themselves ...
(Date:11/24/2014)... N Y, New York (PRWEB) November 24, 2014 ... firm, announced today that it has received national Tier recognition ... “Best Law Firms.” Achieving a tiered ranking signals a unique ... , “We are very proud to receive this honor and ... firm has made this important honor and ranking possible,” said ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... 2014 The report, “Market Snapshot: ... 2020 - Asia-Pacific” provides quantitative analysis of the ... minimally invasive body contouring devices, non-invasive body contouring ... market size data by revenue and volume over ... China, Japan, South Korea, Australia and India. It ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
... adipose stem cell research were not discovered in ... this promising revolution in medicine was inspired via ... popular procedure developed and perfected by renowned Beverly ... researcher and former student of Dr. Ellenbogen's, Dr. ...
... with disabilities or mobility impairments can be tested for,peripheral arterial ... ... Summit Doppler,s Vista AVS, GOLDEN, Colo., July 8 ... today a significant,upgrade to the Vista AVS, a full-featured arterial ...
... billion people suffer from preventable, treatable diseases around,the ... director Global Health Progress, TOYAKO, Japan, July ... World Health Organization (WHO) and,the Drugs for Neglected ... to,recognize the importance of neglected diseases as a ...
... Squibb, an,international pharmaceutical manufacturer, has agreed to reduce ... around,the country at a combined cost of $3.65 ... U.S. Environmental Protection Agency and U.S. Department,of Justice ... federal court in Evansville, Ind., New,York-based Bristol-Myers Squibb ...
... to respond to Herceptin , , TUESDAY, July 8 (HealthDay News) ... patient is likely to respond to treatment with the drug ... Drug Administration. , The SPOT-Light HER2 CISH kit ... regulates the growth of cancer cells, are in tumor tissue. ...
... 8 At 12:00 noon on July 8, ... & Christensen, P.C.,filed the first drug product liability ... Court affirmed former Governor Engler,s grant of immunity,to ... liability lawsuit was filed in the United,States District ...
Cached Medicine News:Health News:Leading Plastic Surgeons Reveal Revolution in Stem Cell Research Has its Roots in Beverly Hills Plastic Surgery 2Health News:Leading Plastic Surgeons Reveal Revolution in Stem Cell Research Has its Roots in Beverly Hills Plastic Surgery 3Health News:Summit Doppler Announces the Seated ABI for the Diagnosis of Peripheral Arterial Disease 2Health News:Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases 2Health News:Bristol-Myers Squibb Agrees to Clean Air Act Upgrades 2Health News:Bristol-Myers Squibb Agrees to Clean Air Act Upgrades 3Health News:FDA Approves Genetic Test for Breast Cancer 2Health News:National Class Action Filed Against Manufacturer of Digitek(R) (Prescription Drug) in Federal Court in Michigan 2
Allows surgeons to successfully complete coronary artery bypass without cross clamping or side biting. Saphaneous vein grafts may be attached to the aorta without sutures....
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
Medicine Products: